Marktanalyse - Smoking Addiction - Pipeline Review, H2 2016

Global Markets Direct
12.2016
111 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Smoking Addiction - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smoking Addiction — Pipeline Review, H2 2016, provides an overview of the Smoking Addiction (Central Nervous System) pipeline landscape.

In smoking addiction, people experience an uncontrollable dependence on cigarettes, which on stopping will cause severe mental, emotional or physical reactions. People addicted to smoking develop tolerance to nicotine. Nicotine acts on acetylcholine receptors causing the body to react to nicotine at these receptors in the same manner as it responds to acetylcholine. This leads to alterations in the activity and physiological functions of many brain systems. This causes structural and functional changes in the brains of smokers. Upon sudden nicotine withdrawal, the brain and other parts of the body get disturbed, leading to a condition called withdrawal syndrome. The body usually takes time to function in the absence of nicotine. The effects of smoking withdrawal stem from the lack of nicotine that can be overcome by nicotine replacement therapies such as the use of nicotine patch or nicotine chewing gum.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smoking Addiction — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Smoking Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smoking Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Smoking Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 6, 7, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Smoking Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Smoking Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Smoking Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Smoking Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Smoking Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Smoking Addiction (Central Nervous System)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Smoking Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Smoking Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Smoking Addiction Overview 9

Therapeutics Development 10

Pipeline Products for Smoking Addiction - Overview 10

Pipeline Products for Smoking Addiction - Comparative Analysis 11

Smoking Addiction - Therapeutics under Development by Companies 12

Smoking Addiction - Therapeutics under Investigation by Universities/Institutes 14

Smoking Addiction - Pipeline Products Glance 15

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Smoking Addiction - Products under Development by Companies 18

Smoking Addiction - Products under Investigation by Universities/Institutes 19

Smoking Addiction - Companies Involved in Therapeutics Development 20

Aradigm Corp 20

Arena Pharmaceuticals Inc 21

Astraea Therapeutics LLC 22

Bioprojet SCR 23

CoMentis Inc 24

Embera NeuroTherapeutics Inc 25

Euthymics Bioscience Inc 26

Invion Ltd 27

Jeil Pharmaceutical Co Ltd 28

Johnson & Johnson 29

Lotus Pharmaceutical Co Ltd 30

Marinus Pharmaceuticals Inc 31

NAL Pharmaceuticals Ltd 32

Pfizer Inc 33

Selecta Biosciences Inc 34

Seoul Pharma Co Ltd 35

Zynerba Pharmaceuticals Inc 36

Smoking Addiction - Therapeutics Assessment 37

Assessment by Monotherapy Products 37

Assessment by Combination Products 38

Assessment by Target 39

Assessment by Mechanism of Action 41

Assessment by Route of Administration 43

Assessment by Molecule Type 45

Drug Profiles 47

(metyrapone + oxazepam) - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

AKR-214 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

amitifadine - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Anatabine - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

AT-1001 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

BP-1.4979 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

ganaxolone - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

GTS-21 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

JLP-1603 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

JNJ-39393406 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

lorcaserin hydrochloride - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

nadolol - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

NFL-101 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

NIC-7DT - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

nicotine bitartrate - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

nicotine bitartrate - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

Nicotine Vaccine - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

PF-06413367 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

SEL-070 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Small Molecule to Antagonize Cannabinoid Receptor for Smoking Addiction - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Small Molecule to Inhibit Sodium Dependent Dopamine, Noradrenaline and Serotonin Transporters for Appetite Suppression and Smoking Cessation - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Small Molecules to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

Small Molecules to Antagonize CHRNA3 and CHRNB4 for Smoking Cessation - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

SPO-1105 - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

URB-694 - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

Smoking Addiction - Dormant Projects 95

Smoking Addiction - Discontinued Products 97

Smoking Addiction - Product Development Milestones 98

Featured News & Press Releases 98

Nov 17, 2015: Invion Phase 2 Smoking Cessation Data: Results of Ongoing Analysis 98

Oct 05, 2015: Invion Successfully Completes Phase 2 Study of INV102 to Aid Smoking Cessation 99

Jun 29, 2015: Invion completes dosing in key phase II clinical trial of oral INV102 in smoking cessation 100

Feb 02, 2015: Invion completes enrolment in its phase II trial of oral INV102 (nadolol) in smoking cessation 101

Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation 102

Nov 04, 2014: Lorcaserin Meets Primary Endpoint And Confirms Proof-Of-Concept As Potential Aid For Smoking Cessation In Investigational Phase II Clinical Study 103

Nov 03, 2014: Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation 103

Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform 104

May 09, 2014: Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ (lorcaserin HCl) CIV by 50% 105

Jan 29, 2014: FDA clears path for 'Smoking Cessation” clinical trial of INV102 (nadolol) 105

Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial 106

Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL 106

Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs 107

Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint 108

Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation 108

Appendix 110

Methodology 110

Coverage 110

Secondary Research 110

Primary Research 110

Expert Panel Validation 110

Contact Us 110

Disclaimer 111





List of Tables

Number of Products under Development for Smoking Addiction, H2 2016 10

Number of Products under Development for Smoking Addiction - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Development, H2 2016 16

Comparative Analysis by Unknown Stage Development, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Smoking Addiction - Pipeline by Aradigm Corp, H2 2016 20

Smoking Addiction - Pipeline by Arena Pharmaceuticals Inc, H2 2016 21

Smoking Addiction - Pipeline by Astraea Therapeutics LLC, H2 2016 22

Smoking Addiction - Pipeline by Bioprojet SCR, H2 2016 23

Smoking Addiction - Pipeline by CoMentis Inc, H2 2016 24

Smoking Addiction - Pipeline by Embera NeuroTherapeutics Inc, H2 2016 25

Smoking Addiction - Pipeline by Euthymics Bioscience Inc, H2 2016 26

Smoking Addiction - Pipeline by Invion Ltd, H2 2016 27

Smoking Addiction - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 28

Smoking Addiction - Pipeline by Johnson & Johnson, H2 2016 29

Smoking Addiction - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2016 30

Smoking Addiction - Pipeline by Marinus Pharmaceuticals Inc, H2 2016 31

Smoking Addiction - Pipeline by NAL Pharmaceuticals Ltd, H2 2016 32

Smoking Addiction - Pipeline by Pfizer Inc, H2 2016 33

Smoking Addiction - Pipeline by Selecta Biosciences Inc, H2 2016 34

Smoking Addiction - Pipeline by Seoul Pharma Co Ltd, H2 2016 35

Smoking Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2016 36

Assessment by Monotherapy Products, H2 2016 37

Assessment by Combination Products, H2 2016 38

Number of Products by Stage and Target, H2 2016 40

Number of Products by Stage and Mechanism of Action, H2 2016 42

Number of Products by Stage and Route of Administration, H2 2016 44

Number of Products by Stage and Molecule Type, H2 2016 46

Smoking Addiction - Dormant Projects, H2 2016 95

Smoking Addiction - Dormant Projects (Contd..1), H2 2016 96

Smoking Addiction - Discontinued Products, H2 2016 97





List of Figures

Number of Products under Development for Smoking Addiction, H2 2016 10

Number of Products under Development for Smoking Addiction - Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy Products, H2 2016 37

Number of Products by Top 10 Targets, H2 2016 39

Number of Products by Stage and Top 10 Targets, H2 2016 39

Number of Products by Top 10 Mechanism of Actions, H2 2016 41

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 41

Number of Products by Routes of Administration, H2 2016 43

Number of Products by Stage and Routes of Administration, H2 2016 43

Number of Products by Molecule Types, H2 2016 45

Number of Products by Stage and Molecule Types, H2 2016 45

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus